Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8933 USD | +10.82% | +21.87% | +10.28% |
Apr. 25 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
Apr. 25 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.28% | 88.39M | |
+25.83% | 661B | |
+27.13% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+14.53% | 231B | |
+5.02% | 200B | |
-9.16% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- Transcript : HOOKIPA Pharma Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 03